Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM.
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa). This prevents the conversion of fibrinogen to fibrin and inhibits clot formation.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin and factor Xa, thereby inhibiting coagulation cascade.
Continuous intravenous infusion: initial bolus 80 units/kg (max 10,000 units) followed by infusion at 18 units/kg/hour (usual adult dose 1,000-2,000 units/hour). For prophylactic use: subcutaneous 5,000 units every 8-12 hours.
Initial adult dose: 5,000 units IV bolus, followed by continuous IV infusion at 1,000–2,000 units/hour; or 10,000–20,000 units subcutaneously every 12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
Dose-dependent: 30–60 min after 25 U/kg IV, 60–90 min after 100 U/kg IV, 150 min after 400 U/kg IV. Terminal half-life: ~1.5 h (low dose) to ~5 h (high dose). Context: nonlinear due to saturable clearance mechanisms.
Mean 1.5 hours (range 1-2 hours) after IV administration; increases with dose (e.g., 25,000 U IV: ~2.5 h). Clinical context: nonlinear pharmacokinetics; half-life prolonged in hepatic or renal impairment.
Renal (minimal, saturable) and reticuloendothelial system (heparinase). Unchanged heparin: negligible urinary excretion. Metabolites: desulfated heparin via hepatic and extrahepatic heparinase; inactive fragments cleared renally.
Primarily renal (heparin is metabolized and excreted as uroheparin and other metabolites; up to 50% of administered dose appears in urine as unchanged heparin, but clearance is dose-dependent and nonlinear).
Category A/B
Category C
Anticoagulant
Anticoagulant